Frontiers in Clinical Drug Research - Anti-Cancer Agents.

Format:

Book

Author/Creator:

Atta-ur-Rahman.

Contributor:

Atta-ur-Rahman, Editor.

Series:

Frontiers in Clinical Drug Research - Anti-Cancer Agents

Language:

English

Subjects (All):

Chemistry.

Physical Description:

1 online resource (322 pages)

Edition:

1st ed.

Place of Publication:

UAE : Bentham Science Publishers, 2021.

Summary:

Frontiers in Clinical Drug Research - Anti-Cancer Agents is a book series intended for pharmaceutical scientists, postgraduate students and researchers seeking updated and critical information for developing clinical trials and devising research plans in anti-cancer research. Reviews in each volume are written by experts in medical oncology and clinical trials research and compile the latest information available on special topics of interest to oncology and pharmaceutical chemistry researchers. The eighth volume of the book features reviews on these topics: - Key data management elements in clinical trials for oncological therapeutics - Prospects for therapeutic targeting of microRNAs in brain tumors - Breast cancer vaccines: current status and future approach - Desmocollin-3 and cancer - MDM2-p53 antagonists under clinical evaluation: a promising cancer targeted therapy for cancer patients harbouring wild-type tp53 - Towards targeted therapy: anticancer agents targeting cell organelle mitochondria - Anticancer therapeutic strategies in gliomas: chemotherapy, immunotherapy, and molecularly targeted therapy in adults Audience: Pharmaceutical Scientists, Medicinal Chemists, Clinical Oncologists, Researchers in Pre-clinical studies and clinical trials.

Contents:

Cover

Title

Copyright

End User License Agreement

Contents

Preface

List of Contributors

Key Data Management Elements in Clinical Trials for Oncological Therapeutics

Daniel Liu1,*, Hualong Sun1, Yan Bo2 and Joey Wang2

1. INTRODUCTION

2. CDISC STANDARDS APPLICATIONS TO ONCOLOGY CLINICAL TRIALS

2.1. Data Collection Based on CDASH Standards in Oncology Studies

2.2. The SDTM Data Mapping Process of Oncology Clinical Trials

2.3. The Data Analysis of Oncology Clinical Trials by Implementing ADaM Datasets

2.4. The Developing Status of Therapeutic Area Data Standards User Guide

3. KEY PERSPECTIVES OF CLINICAL DATA IN CLINICAL TRIAL DEVELOPMENT OF CANCER DRUGS

4. KEY CONSIDERATIONS OF CRF DESIGNS IN CANCER TRIALS

4.1. History of Tumor Therapy/Prior Treatment

4.2. Tumor Diagnosis

4.3. Status Rating of Physical Performances

4.4. Questionnaire of Quality of Life

4.5. Body Weight

4.6. Medical Diagnosis with Molecular Biology Techniques

4.7. Biomarkers Measures

4.8. Imaging Evaluations and Tumor Lesion Measurements

4.9. Dose Given/Administration and Dose Adjustments

4.10. Adverse Reactions

4.11. Therapeutic Completion and Trial Summary

5. RISK-BASED DATA MANAGEMENT

6. DATA VALIDATION AND MANAGEMENT IN ONCOLOGY STUDIES

6.1. Data Management of Subjects' Eligibility with Tumor Staging Status

6.2. Data Management on Historical Anti-tumor Treatment

6.3. Data Management on Dose Administration

6.4. Data Management on Terminated Criteria

6.5. Data Management on Efficacy Assessment

6.6. Data Management on Safety Assessment

6.7. Data Management on External Data

7. MANAGEMENT OF INDEPENDENT DATA MONITORING COMMITTEES IN ONCOLOGY STUDIES

7.1. Roles of DMC in Interim Analysis of Oncology Studies.

7.2. Management of Statistical Processes by DMC in Oncology Studies

7.3. DMC Interaction with Sponsors

7.4. DMC Interaction with Regulatory Authorities

CONCLUDING REMARKS

CONSENT FOR PUBLICATION

CONFLICT OF INTEREST

ACKNOWLEDGEMENTS

REFERENCES

Prospects for Therapeutic Targeting of MicroRNAs in Brain Tumors

Ilgiz Gareev1 and Ozal Beylerli1,*

2. BIOGENESIS AND FUNCTION OF MIRNA

3. MIRNA-BASED THERAPEUTIC STRATEGIES

4. MIRNAS AND BRAIN TUMORS

4.1. Role of miRNAs Dysregulation in Glioma

4.2. Role of miRNAs Dysregulation in Meningioma

4.3. Role of miRNAs Dysregulation in PA

4.4. Role of miRNAs Dysregulation in Medulloblastoma

4.5. Metastasis-associated miRNA

5. DEVELOPMENT AND THERAPEUTICS OF MIRNA-BASED DRUGS FOR BRAIN TUMORS

5.1. Strategies for miRNA-based Drugs Administration to Brain Tumors

5.1.1. Intracerebroventricular and Intrathecal Administration

5.1.2. Transnasal Administration

5.2. Delivery Methods of miRNA-based Drugs to the Brain Tumors

5.2.1. MiRNA Delivery via Exosomes

5.2.2. MiRNAs Delivery Through Nanoparticles

5.2.3. MiRNA Delivery Through Viral Vectors

6. CONCLUSIONS AND FUTURE PERSPECTIVES

Breast Cancer Vaccines: Current Status and Future Approach

Aytül Gül1,2, Sedef Erkunt Alak3, Ceren Gül4, Tuğba Karakavuk4, Hüseyin Can2,3, Muhammet Karakavuk2,5, Ahmet Efe Köseoğlu3, Mert Döşkaya2,6, Aysu Değirmenci Döşkaya2,6, Elif Esin Hameş Tuna1, Cemal Ün2,3, Adnan Yüksel Gürüz2,6 and Levent Yeniay2,7,*

INTRODUCTION

PROBABLE VACCINE ANTIGENS

Tumor Association Antigens

Breast Cancer Stem Cell Oncoantigens

Neoantigens

VACCINE PLATFORM TECHNOLOGIES FOR BREAST CANCER

Peptide Vaccines

Cell Based Vaccines

Whole Tumor Cell Vaccines.

Dendritic Cell Based Vaccines

Nucleic Acid Vaccines

DNA Vaccines

RNA Vaccines

Viral Vector-Based Vaccines

FUTURE PERSPECTIVE

CONCLUSION

LIST OF ABBREVIATIONS

Desmocollin-3 and Cancer

Chandreshwar Shukla1, Nayan K Jain1 and Bakulesh Khamar2

DESMOCOLLIN-3

DSC3 Gene and its Expression in Cancer

Mutations of DSC3 in Cancer

DSC3 Protein Expression

DSC3 Expression in Cancer

DSC3 Positive Cancer

DSC3 Negative Cancer

Correlation of DSC3 in Cancer

Correlation with TP53 Family

Correlation with Other Desmosomal Components

Correlation with Hallmarks of Cancer

Significance of DSC3 as a Biomarker

DSC3 as a Diagnostic Biomarker

DSC3 as a Prognostic Marker

DSC3 Expression and the Effect of Therapeutic Agents

Chemotherapeutic Agents

Tyrosine Kinase Inhibitors

Hypomethylating/Demethylating Agents

DSC3 and Signaling Pathways

DSC3 and Tumor-infiltrating Immune Cells

DSC3 and Immunotherapy

Active Immunotherapy

MDM2-p53 Antagonists Under Clinical Evaluation: A Promising Cancer Targeted Therapy for Cancer Patients Harbouring Wild-Type TP53

Maryam Zanjirband1,*

The TP53 Acts as a Tumour Suppressor Gene Through Inducing Cell Cycle Arrest and Apoptosis

Use of MDM2-p53 Antagonists to Target p53-MDM2 Interaction for Cancer Therapy

NOTES

Towards Targeted Therapy: Anticancer Agents Targeting Cell Organelle Mitochondria

Meghana Manjunath1 and Bibha Choudhary1,*

Understanding the Mitochondrial Physiology.

Bioenergetics of Mitochondria

Calcium Signalling in Mitochondria

Mitochondrial Fission and Fusion

Reactive Oxygen Species (Ros) Production In Mitochondria

Mitochondria and Cell Death

Role of the Mitochondria in Biosynthetic Pathways

Oncogenic and Tumour-Suppressive Pathways Regulating Mitochondrial Metabolism and Biogenesis

Mitochondrial Metabolism and the Immune System

Mitochondrial Genome

Mitochondrial Mutations in Cancer

Transcriptomic Studies for Understanding Mitochondria

Cancer Stem Cells and Mitochondria

Targeting Mitochondria in Cancer Therapy

Targeting Apoptosis

BCL2 Family Inhibitors

Targeting Mitochondrial Metabolism

Anaplerosis as a Target

Targeting the TCA cycle

Targeting the ETC

Targeting Mitochondrial Fission and Fusion

Targeting ROS

Targeting Cancer Stem Cells(CSCs) Using Antibiotics

Targeting Mitochondrial Mutations via Immune Therapy

Online Resource Toolkit Available to Understand Mitochondrial Genomics

FUTURE PERSPECTIVES

Anticancer Therapeutic Strategies in Gliomas: Chemotherapy, Immunotherapy, and Molecularly Targeted Therapy in Adults

Xiaoyan Hu1,2,*, †, Kexun Lian3,†, Mengmeng Wang3,† and Xun Zhang4,*

CHEMOTHERAPY

MOLECULARLY TARGETED THERAPY

MGMT Methylation

IDH Mutations

TP53 Mutations

ATRX Mutations

TERT Mutations

Chromosomal Deletions

IMMUNOTHERAPY

Personalised Peptide Vaccines

Dendritic Cell (DC) Vaccine Therapy

CAR-T Cell Therapy

Checkpoint Blockade Therapy

Oncolytic Virus Therapy

FUTURE DIRECTIONS

Subject Index

Back Cover.

Notes:

Description based on publisher supplied metadata and other sources.

Other Format:

Print version: Atta-ur-Rahman Frontiers in Clinical Drug Research - Anti-Cancer Agents: Volume 8

ISBN:

9781681089317

1681089319

OCLC:

1293253550